Your session is about to expire
← Back to Search
Beta-2 Agonist
2 for Emphysema
Phase 3
Waitlist Available
Research Sponsored by Sumitomo Pharma America, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
The purpose of this study is to assess the bronchodilator effect and safety of multiple daily doses of arformoterol administered for 12 weeks as maintenance treatment in patients with COPD
Eligible Conditions
- Emphysema
- Chronic Obstructive Pulmonary Disease
- Chronic Bronchitis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
5Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: 3Experimental Treatment1 Intervention
Arformoterol 15 mcg BID and placebo MDI
Group II: 2Experimental Treatment1 Intervention
Arformoterol 25 mcg BID and Placebo MDI
Group III: 1Experimental Treatment1 Intervention
Arformoterol 50 mcg QD and placebo MDI
Group IV: 4Active Control1 Intervention
Salmeterol MDI 42 mcg BID and placebo inhalation solution
Group V: 5Placebo Group1 Intervention
Placebo MDI and placebo inhalation solution
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Arformoterol
FDA approved
Find a Location
Who is running the clinical trial?
Sumitomo Pharma America, Inc.Lead Sponsor
242 Previous Clinical Trials
52,395 Total Patients Enrolled
4 Trials studying Emphysema
1,497 Patients Enrolled for Emphysema
SunovionLead Sponsor
191 Previous Clinical Trials
49,955 Total Patients Enrolled
4 Trials studying Emphysema
1,497 Patients Enrolled for Emphysema
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger